Saturday 17 October 2026
Export PACS’s income statement to Excel — free account
PACS Group, Inc.
PACS Healthcare Medical Care Facilities
PACS Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 29.3% from fiscal 2024. In the quarter to June 2026, revenue grew 9.07%, EPS grew 45.5%, free cash flow grew 220.5% and total debt fell 4.30%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
46.91
0.84
−1.76%
Follow PACS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
12.60 | 31.47 | 20.72 | 25.08 |
P/S ratio |
0.42 | 1.13 | 0.93 | 1.21 | |
P/FCF ratio |
5.47 | 20.01 | 13.22 | 14.77 | |
P/Operating CF |
10.50 | (1,768.67) | 21.35 | 49.75 | |
P/B ratio |
2.45 | 6.30 | 4.84 | 6.04 | |
Price to Tangible BV |
2.66 | 6.78 | 5.18 | 6.44 | |
EV/Sales |
0.40 | 1.16 | 0.94 | 1.23 | |
EV/EBITDA |
5.97 | 16.69 | 11.42 | 14.17 | |
EV/Operating CF |
4.34 | 15.21 | 10.38 | 11.90 | |
EV/FCF |
5.21 | 20.52 | 13.34 | 14.95 | |
Quick Ratio |
0.88 | 0.90 | 0.91 | 0.84 | |
Current Ratio |
0.94 | 1.07 | 1.00 | 0.91 | |
Net Debt/EBITDA |
(1.01) | 1.37 | 0.33 | 0.63 | |
Debt/Assets |
4.50% | 6.25% | 5.18% | 4.35% | |
Debt/Equity |
0.29 | 0.37 | 0.28 | 0.22 | |
Asset Turnover |
1.01 | 0.98 | 0.97 | 0.99 | |
Operating CF/Net income |
3.91 | (0.06) | 2.93 | 1.77 | |
Capex/Depreciation |
(1.19) | (3.11) | (1.16) | (1.27) | |
Interest Coverage |
10.11 | 11.04 | 18.69 | 18.10 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
7.63% | 8.36% | 7.91% | 8.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.93% | 1.16% | 1.43% | 1.81% | |
Graham Net Nets |
(1.69) | (0.59) | (0.70) | (0.53) | |
Graham Number |
11.72 | 12.94 | 15.21 | 16.43 | |
Earnings Yield |
7.94% | 3.18% | 4.83% | 3.99% | |
Free Cash Flow Yield |
18.30% | 5.00% | 7.56% | 6.77% | |
Revenue per Share |
8.59 | 8.69 | 9.04 | 9.03 | |
Operating CF per Share |
1.31 | (0.02) | 1.50 | 0.86 | |
Capex per Share |
(0.11) | (0.32) | (0.14) | (0.17) | |
Free Cash Flow per Share |
1.19 | (0.34) | 1.37 | 0.69 | |
Cash per Share |
2.27 | 1.26 | 1.58 | 1.04 | |
Shareholders Equity per Share |
5.60 | 6.10 | 6.64 | 7.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.60 | 6.10 | 6.64 | 7.05 | |
Free Cash Flow |
186.79 | (53.75) | 214.51 | 108.98 | |
Working Capital |
(70.87) | 68.31 | (5.42) | (92.70) | |
Capital Expenditures |
(18.01) | (50.36) | (21.83) | (26.53) | |
Net Current Asset Value |
(3,623.23) | (3,561.85) | (3,553.22) | (3,578.57) | |
EV/EBIT |
7.14 | 19.86 | 13.34 | 16.63 | |
Capex to Sales |
0.01 | 0.04 | 0.02 | 0.02 | |
Price to Operating Income |
7.49 | 19.37 | 13.23 | 16.43 | |
| Other line items | |||||
Average Receivables |
659.34 | 709.31 | 737.46 | 706.84 | |
Average Payables |
180.11 | 183.65 | 189.64 | 166.45 | |
Average Assets |
5,071.80 | 5,413.47 | 5,578.96 | 5,579.25 | |
Average Common Equity |
771.83 | 834.07 | 899.23 | 964.03 |
Columns are period end dates